Collegium Pharmaceutical, Inc.
NASDAQ:COLLDrug Manufacturers - Specialty & Generic
-$0.24 today
- Market cap
- $805.79M
- Beta
- 0.75
- P/E (TTM)
- 14.3
- EPS (TTM)
- $2.34
Volume 0.49M
Average 0.50M
COLL Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Collegium Pharmaceutical, Inc.NASDAQ: COLL
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables growth accelerates
Q1 FY2026 accounts receivables of $17.43M (cash outflow) rose 10155.3% year over year, ahead of the -99.4% change in trailing-twelve-month accounts receivables.
Context
- Accounts receivables amounted to 2.2% of revenue in FY2025, up 1.5 pp from a year earlier.
- Accounts receivables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +10155.3% holds above the trailing-twelve-month pace of -99.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 17.2M USD
- Year-over-year change
- +489.8%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 17.2M | +489.8% |
| FY2024 | 2024-12-31 | (4.41M) | -222.8% |
| FY2023 | 2023-12-31 | 3.59M | +116.5% |
| FY2022 | 2022-12-31 | (21.78M) | +3.3% |
| FY2021 | 2021-12-31 | (22.52M) | — |
Accounts Receivables vs competitors
How COLL compares with its peers on the latest reported figures
- COLL's LTM Mar 2026 accounts receivables of $60K is the smallest of the 3 companies compared; the peer median is $9.22M.
- Its year-over-year change of -99.4% is the lowest of 3, against a peer median of +261.9%.
- Accounts receivables amounts to 0.0% of revenue for COLL, versus a peer median of 5.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $20.87M | +571.9% | +72.9% | 2.8% | |
| LTM Mar 2026 | $2.42M | -48.1% | — | 7.2% | |
| LTM Mar 2026 | $60K | -99.4% | — | 0.0% | |
LTGOLatigo Biotherapeutics Inc. | — | — | — | — | — |
| Peer median (excluding COLL) | $9.22M | +261.9% | +72.9% | 5.0% | |
Competitors are the stored peer set for COLL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 71.52M | (25M) | 48.16M | 69.19M | 62.87M |
| Depreciation & Amortization | 68.92M | 138.94M | 149.26M | 169.16M | 220.82M |
| Deferred Income Tax | (78.04M) | (8.39M) | (2.15M) | (26.81M) | (25.66M) |
| Stock-Based Compensation | 24.26M | 22.87M | 27.14M | 32.4M | 41.91M |
| Change in Working Capital | 13.49M | (12.71M) | 21.73M | (54.98M) | 3.76M |
| Accounts Receivables | (22.52M) | (21.78M) | 3.59M | (4.41M) | 17.2M |
| Inventory | (2.3M) | 48.27M | 14.17M | 13.93M | (5.35M) |
| Accounts Payables | (5.83M) | (707K) | 5.06M | (11.28M) | 6.72M |
| Other Working Capital | 44.13M | (38.5M) | (1.09M) | (53.21M) | (14.81M) |
| Other Non-Cash Items | 3.42M | 8.52M | 30.62M | 16.02M | 25.62M |
| Operating Cash Flow | 103.56M | 124.23M | 274.75M | 204.98M | 329.32M |
| Capital Expenditures | (1.94M) | (1.62M) | (461K) | (1.65M) | (1.74M) |
| Acquisitions (Net) | 0 | (572.07M) | 0 | (267.54M) | 0 |
| Purchases of Investments | 0 | 0 | (92.35M) | (111.17M) | (126.97M) |
| Sales of Investments | 0 | 0 | 22M | 92.6M | 65.18M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (1.94M) | (573.69M) | (70.81M) | (287.76M) | (63.53M) |
| Debt Repayment | (50M) | 442.68M | (65.92M) | 7.52M | (70.38M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 5.64M |
| Common Stock Repurchased | (47.86M) | (14.06M) | (75M) | (60.03M) | (25.1M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 8.56M | 8.1M | 740K | (8.1M) | (20.4M) |
| Financing Cash Flow | (89.3M) | 436.72M | (140.18M) | (60.6M) | (110.25M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 12.31M | (12.74M) | 63.76M | (143.38M) | 155.55M |
| Free Cash Flow | 101.61M | 122.61M | 274.29M | 203.33M | 327.58M |
Collegium Pharmaceutical, Inc.
NASDAQ:COLL
Intrinsic Alpha fair value
Locked
Current Price
$25.93
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.